Altimmune (ALT) Stock Forecast & Price Target

Altimmune is well-positioned to execute on pemvidutide's late-stage development plan, with a well-capitalized balance sheet and favorable clinical trial updates and catalysts in both the MASH and AUD/ALD markets. Furthermore, their pro forma cash, cash equivalents, and short-term investments from recent financing provides funding through the Pharmacyclics 52-week data readout in 2029, resulting in a projected peak annual revenue of over $4.8 billion.

Altimmune is a late-stage biopharmaceutical company with a key candidate, pemvidutide, that has potential in three indications, but the company faces significant challenges due to the crowded competitive landscape in the areas of NASH and obesity. This competition, combined with the company's early stage of development, creates commercial risks that could adversely affect its business prospects, operating results, and stock price. Additionally, Altimmune's reliance on government contracts to fund its pipeline development may require future capital requirements, adding another layer of risk. Despite its successful IMPACT trial and potential advantages over competitors, Altimmune's success is dependent on the development and commercialization of pemvidutide, which may face regulatory uncertainties and face competition from more advanced candidates.